Dasatinib, an ABL tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukaemia (CML), can downregulate the inhibitory receptor NKG2A on patient NK cells, which promotes NK cell function against CML cells [30]. Here, KLRC1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.